Maresin-1 Ameliorates Sepsis-Induced Microglial Activation Through Modulation of the P38 MAPK Pathway

被引:0
|
作者
Dai, Maosha [1 ,2 ,3 ]
Sun, Shujun [1 ,2 ,3 ,4 ]
Dai, Yan [1 ,2 ,3 ]
Dou, Xiaoke [1 ,2 ,3 ]
Yang, Juexi [1 ,2 ,3 ]
Chen, Xiangdong [1 ,2 ,3 ]
Yang, Dong [2 ,3 ,4 ]
Lin, Yun [1 ,2 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Anesthesiol, 1277,Jiefang Ave, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Anesthesia & Crit Care Med, Tongji Med Coll, 1277,Jiefang Ave, Wuhan 430022, Peoples R China
[3] Huazhong Univ Sci & Technol, Key Lab Anesthesiol & Resuscitat, Minist Educ, Wuhan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pain, 1277,Jiefang Ave, Wuhan 430022, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuroinflammation; Microglia; Sepsis; Maresin-1; NEUROINFLAMMATION; MODEL; REGENERATION; INFLAMMATION; PHYSIOLOGY; RESOLUTION;
D O I
10.1007/s11064-024-04280-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is a life-threatening disease characterized by a dysregulated immune response to infection, often leading to neuroinflammation. As a known immunomodulator, Maresin-1 (MaR1) may have potential applications in the treatment of sepsis-induced neuroinflammation, but its effects in this context are unknown. We used a mouse cecum ligation and puncture (CLP)-induced sepsis model and an in vitro lipopolysaccharide (LPS)-induced neuroinflammatory model of BV2 microglia. Expression of microglial cell markers (IBA1, CD11B, CD68, CD86 and CD206) and pro-inflammatory markers (iNOS and COX2) was assessed. The role of MaR1 in regulating the P38 MAPK pathway was explored using the P38 MAPK inhibitor SB203580. In the CLP model, an increased proportion of M1-type microglia was observed, and MaR1 was able to reverse it. However, the combination of SB203580 and MaR1 did not enhance the therapeutic effect compared to SB20580 alone. In vitro experiments, MaR1 inhibited LPS-induced P38 MAPK nuclear translocation and decreased the expression of pro-inflammatory markers such as iNOS and COX2. As with the animal results, no stacking effect could be obtained with the co-administration of SB203580 and MaR1. Our findings suggest that MaR1 attenuates sepsis-induced neuroinflammation mainly by inhibiting phosphorylation of P38 MAPK in microglial cells. This suggests that MaR1 may have a potential therapeutic role in the treatment of sepsis neuroinflammation.Graphical AbstractUnder sepsis, the phosphorylation of P38 MAPK in the brain is increased, which may cause resting microglia in the brain in the transformation to M1-type microglia. At the same time, P38 MAPK in microglia translocates to the nucleus and increases its phosphorylation level, which may promote microglia to trigger neuroinflammation and further induce neuronal degeneration. MaR1 can inhibit the above process. This figure was created by Figdraw Maresin-1 reduces the proportion of M1-type microglia in sepsis mice.Maresin-1 reduces the expression levels of iNOS and COX2 in microglia in vitro.Maresin-1 affects nuclear translocation of p38 MAPK in microglia.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα
    Xing, Bin
    Bachstetter, Adam D.
    Van Eldik, Linda J.
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [32] Unc119 regulates myofibroblast differentiation through the activation of Fyn and the p38 MAPK pathway
    Vepachedu, Ramarao
    Gorska, Magdalena M.
    Singhania, Neil
    Cosgrove, Gregory P.
    Brown, Kevin K.
    Alam, Rafeul
    JOURNAL OF IMMUNOLOGY, 2007, 179 (01): : 682 - 690
  • [33] Pulegone ameliorates inflammation and oxidative stress in L-arginine-induced acute pancreatitis in mice by regulating the activation of p38 MAPK pathway
    Xiong, Qinpan
    Du, Chao
    Xia, Wei
    Tang, Kang
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (04) : 755 - 760
  • [34] Ultraviolet A induced modulation of gap junctional intercellular communication by P38 MAPK activation in human keratinocytes
    Bellei, Barbara
    Mastrofrancesco, Arianna
    Briganti, Stefania
    Aspite, Nicaela
    Ale-Agha, Niloofar
    Sies, Helmut
    Picardo, Mauro
    EXPERIMENTAL DERMATOLOGY, 2008, 17 (02) : 115 - 124
  • [35] Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway
    Koike, T
    Atsumi, T
    LUPUS, 2005, 14 (10) : 799 - 801
  • [36] Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL
    Vega, Mario I.
    Aviles-Salas, Alejandro
    Ramon Chalapud, J.
    Huerta-Yepez, Sara
    Hernandez-Pando, Rogelio
    Martinez-Paniagua, Melisa
    Martinez-Miguel, Bernardo
    Hernandez-Atenogenes, Miriam
    Vega, Gabriel G.
    Chen, Haiming
    Berenson, James R.
    Mayani, Hector
    Martinez-Maza, Otoniel
    Bonavida, Benjamin
    BLOOD, 2011, 118 (21) : 1137 - 1137
  • [37] BMI1 Drives Steroidogenesis Through Epigenetically Repressing the p38 MAPK Pathway
    Yu, Jun
    Wu, Yibo
    Li, Hong
    Zhou, Hui
    Shen, Cong
    Gao, Tingting
    Lin, Meng
    Dai, Xiuliang
    Ou, Jian
    Liu, Meiling
    Huang, Xiaoyan
    Zheng, Bo
    Sun, Fei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [38] Galangin ameliorates PTU-induced vitiligo in zebrafish and B16F10 cells by increasing melanogenesis through activation of the p38/JNK MAPK pathway
    Wusiman, Zulipikaer
    Zhang, Ai-Mei
    Zhang, Shu-Shu
    Zhao, Ping-Ping
    Kang, Yu-Tong
    Zhang, Yun
    Li, Zhi-Jian
    Huo, Shi-Xia
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [39] Proteasome inhibitor MG132 induces NAG-1 expression through activation of p38 MAPK pathway
    Shimizu, Sachie
    Kinyamu, Harriet
    Yoshioka, Hiroki
    Kadowaki, Mitsutoshi
    Watanabe, Takashi
    Eling, Thomas
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [40] Downregulation of p38 MAPK Signaling Pathway Ameliorates Tissue-Engineered Corneal Epithelium
    Mao, Yi
    Ou, Shangkun
    Zhu, Chengfang
    Lin, Sijie
    Liu, Xiaodong
    Liang, Minghui
    Yu, Jingwen
    Wu, Yiming
    He, Hui
    Zong, Rongrong
    Lin, Zhirong
    Liu, Zuguo
    Li, Wei
    TISSUE ENGINEERING PART A, 2022, 28 (23-24) : 977 - 989